Shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) have been assigned a consensus recommendation of “Buy” from the nine research firms that are presently covering the company. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $27.00.
A number of brokerages recently issued reports on SNDX. Oppenheimer Holdings Inc. set a $25.00 price objective on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, March 4th. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 29th. Nomura initiated coverage on shares of Syndax Pharmaceuticals in a research note on Wednesday, March 1st. They set a “buy” rating for the company. FBR & Co began coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, March 16th. They set an “outperform” rating and a $27.00 target price for the company. Finally, Cowen and Company began coverage on shares of Syndax Pharmaceuticals in a research report on Friday, March 24th. They set an “outperform” rating on the stock.
WARNING: “Syndax Pharmaceuticals Inc (SNDX) Receives $25.86 Consensus Target Price from Analysts” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/04/20/syndax-pharmaceuticals-inc-sndx-receives-25-86-consensus-pt-from-brokerages-updated-updated.html.
Syndax Pharmaceuticals (NASDAQ:SNDX) traded down 2.22% on Tuesday, reaching $10.99. 27,517 shares of the company were exchanged. Syndax Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $18.03. The firm has a 50-day moving average of $12.81 and a 200 day moving average of $10.78. The firm’s market capitalization is $200.50 million.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Thursday, March 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.11. Syndax Pharmaceuticals had a negative net margin of 3,388.98% and a negative return on equity of 306.05%. The firm earned $0.31 million during the quarter. On average, equities analysts predict that Syndax Pharmaceuticals will post ($3.20) earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. raised its position in shares of Syndax Pharmaceuticals by 33.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 225,000 shares of the company’s stock valued at $1,613,000 after buying an additional 56,228 shares in the last quarter. Elkfork Partners LLC bought a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at approximately $204,000. State Street Corp raised its position in shares of Syndax Pharmaceuticals by 6.5% in the fourth quarter. State Street Corp now owns 58,921 shares of the company’s stock valued at $422,000 after buying an additional 3,599 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $2,521,000. Finally, Laurion Capital Management LP bought a new position in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $305,000. Institutional investors own 62.22% of the company’s stock.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.